Head and neck squamous cell carcinoma (HNSCC) is a highly lethal cancer that annually affects over 60,000 people in the United States (US) and has been traditionally associated with tobacco and ethanol exposure. Recently, the incidence of HPV-induced oropharyngeal squamous cell carcinomas (OPSCC) has seen a rapid increase, especially in the US and other Western countries. Early oral HPV infections do not typically cause any clinical signs or symptoms. Currently, there is no standard screening test to reliably identify High Risk HP-related oral tumors, most of the current tests have been validated for cervical tumor samples and not for saliva or blood. Furthermore, the tests presently in use usually require some sort of confirmatory secondary test.
Performing tests for oral HPV should allow the detection of early‐stage, HPV‐related oral cancer recurrence as well as determine prognosis and overcome some of above issues. Researchers at UC San Diego have developed a DNA PCR-based assay for the detection of the HPV-16 subtype that is associated with approximately ~95% of all HPV-HNSCC.
The test will be useful for detecting HPV in a patient’s sample that can be from the blood, saliva, plasma or tumor.
The highly sensitive HPV test is designed to detect HPV in HNSCC and related cancers. The test can also be used to monitor disease progression in a cancer patient in remission from an HPV-related cancer.
The test has been tested on tumor samples from a cohort of 72 patients with HPV-related oropharyngeal squamous cell carcinoma as well as normal oropharynx tissue from surgical specimens obtained from 25 cancer unaffected controls.
A provisional patent has been submitted and the technology is available to license.
|Patent Cooperation Treaty||Published Application||2019173280||09/12/2019||2018-222|
oral cancer, cancer diagnostics, cancer detection, human papilloma virus, squamous cell carcinoma, HPV 16, high-risk HPV